65,437 trials
Healthy Subjects
Primary: Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin — 1990; 1700; 4390; 3910 ng*hr/mL
Pregnancy
Primary: The Percentage of Patients With a Live Birth — 45; 65 Participants
Cystic Fibrosis
Primary: Relative (Percent) Change From Baseline in Maximal Oxygen Consumption (VO2max) During Cardiopulmonary Exercise Testing (CPET) at Week 24 — -3.5; -6.6 percent change…
Malignant Melanoma
Primary: Maximum Tolerated Dose (MTD) of IMC-20D7S — 20 mg/kg q2w
Insomnia Chronic
Primary: Insomnia Severity Index — 18.6; 18.9; 13.1; 14.0 units on a scale
Hookworm
Primary: Cure Rate (CR) of Mebendazole Against Hookworm — 13; 97.9 percentage of participants cured
Lymphoma, Large B-Cell, Diffuse
Primary: Number of Patients With Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period- Phase 1b — 0; 1; 1 participants
Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine…
Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD63 Compared to the Third CYD…
Graves Disease
Primary: Occurrence of Treatment Emergent Adverse Events (TEAE), Serious Adverse Events (SAE), and Laboratory Abnormalities up to Week 22 Compared to Baseline. — 311; 293; 18; 0…
External Genital Warts
Primary: Number of Participants With Complete Clearance, — 0; 0; 3; 5 participants
Irritable Bowel Syndrome Characterized by Constipation
Primary: Number of Overall Responders - ITT Population — 54; 81; 91 Participants
Autism · Asperger's Syndrome · Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale — 7.79; 15.06 units on a scale
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
Neurotrophic Keratitis
Primary: Complete Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer Defined by Central Reviewer — 70; 29; 30; 71 percentage of participants — p==0.006